Probing the interaction between lipidic drug nanoparticles and low density lipoproteins with SANS
If we want to use nanoparticles (NPs) in biomedical applications, it is of utmost importance to understand their interactions with complex biological media. We have thus started to investigate these interactions using squalene adenosine NPs, which have shown a positive effect in neuroprotection of spinal cord in rodents, and model biological media by combining cryo-TEM, small angle neutron scattering and various spectroscopies. We have already demonstrated that BSA could partially disassemble SqAd NPs by forming SqAd-BSA complexes. In the proposed scheme, the NPs act as ~100 nm reservoirs in the bloodstream and the BSA act as transporter of the SqAd monomeric bioconjugate. Other transporters of lipids in the plasma are lipoproteins, which are large (20-30 nm) hydrosoluble protein-lipid complexes. Previous studies have demonstrated that they were indeed potent transporters of SqAd bioconjugates. The main aim of the proposed experiment is thus to decipher the effect of the low density lipoproteins (LDL) on the size and structure of the SqAd NPs and conversely the effect of the SqAd on the LDL complexes by analyzing several mixtures of both components in D2O.
The data is currently only available to download if you are a member of the proposal team.
The recommended format for citing this dataset in a research publication is in the following format:
Frédéric Gobeaux; GUENOUN; MARTEL Anne; Jean-Philippe Renault and TESTARD. (2020). Probing the interaction between lipidic drug nanoparticles and low density lipoproteins with SANS. Institut Laue-Langevin (ILL) doi:10.5291/ILL-DATA.9-13-857
This data is not yet public
This data is not yet public
ILL has partnered with DataCite as the registration agency
for data persistent identifiers.